TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRAMP mice are a common prostate cancer model, in which 5α-reductase 1 and 5α-reductase 2 expression levels, along with prostate lesions scores, have not been investigated at different time points to further understand prostate carcinogenesis.
|
28493878 |
2017 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, ARPCA suppresses the angiogenic and tumorigenic potential of prototypic androgen/FGF8b-dependent Shionogi 115 mammary carcinoma cells and of androgen/FGF8b/FGF2-dependent TRAMP-C2 prostate cancer cells.
|
25912421 |
2015 |
TNFRSF25
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of 92 (TRAMP x WSB) F2 prostates revealed 25 candidate genes that harbored both a significant cis-eQTL and mRNA expression correlations with an aggressive PC trait.
|
29890952 |
2018 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
ARs with short Q tracts (12Q), which are transcriptionally more active, induce earlier disease in the transgene-induced TRAMP prostate cancer model than alleles with median (21Q) or long (48Q) tracts.
|
17906287 |
2008 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Breeding PSA/hCAR mice to existing transgenic mouse models for prostate cancer (e.g., TRAMP) results in improved mouse models for testing adenovirally-delivered therapeutic genes.
|
15761871 |
2005 |
TNFRSF25
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cross-referencing differentially expressed TRAMP genes to public human prostate array datasets revealed 66 genes with concordant expression in mouse and human PCa; 56 between metastases and normal and 10 between primary tumor and normal tissues.
|
18668517 |
2008 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crossing CLU knockout with TRAMP (prostate cancer prone) mice results in a strong enhancement of metastatic spread.
|
19784068 |
2009 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Curcumin Derivative Epigenetically Reactivates Nrf2 Antioxidative Stress Signaling in Mouse Prostate Cancer TRAMP C1 Cells.
|
29228771 |
2018 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model.
|
22210719 |
2012 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the knock down of YAP1 expression or the inhibition of YAP1 function by Verteporfin in TRAMP prostate cancer mice significantly suppresses tumor recurrence following castration.
|
29383141 |
2017 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, transfer of Gprc6a deficiency onto a TRAMP mouse model of prostate cancer significantly retarded prostate cancer progression and improved survival of compound Gprc6a(-/-) /TRAMP mice.
|
21681779 |
2012 |
TNFRSF25
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
First, a transgenic mouse model of prostate cancer (transgenic adenocarcinoma of mouse prostate; TRAMP) was used to determine the role of energy balance on SIRT1 expression and the effect of cancer stage on SIRT1 and hypermethylated in cancer-1 (HIC-1).
|
17638871 |
2007 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, EGPs, AGEs, and their conditioned medium (CM) from macrophages are applied to human prostate cancer (PCa) cells with different etiology (LNCaP and PC-3) and murine PCa cells (TRAMP-C2) to determine their direct and indirect effects on PCa cell proliferation.
|
29082675 |
2018 |
TNFRSF25
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Gene-modified DC vaccination mediated regression of established, specific gene-expressing, TRAMP-C1 prostate cancer cell tumors.
|
15678150 |
2005 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that in mouse prostate cancer TRAMP-C1 cells epididymal fat extracts from high-fat diet-fed obese mice stimulate androgen-independent cell growth more significantly than those from low-fat diet-fed lean mice or genetically obese leptin-deficient ob/ob mice in correlation with leptin concentrations.
|
18718531 |
2008 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we screened TRAMP-derived C2 cell line for the alterations using different microarray approaches, and compared it to human prostate cancer.
|
18649357 |
2008 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that genetic ablation of Nr2f6 significantly improves survival in the murine transgenic TRAMP prostate cancer model.
|
26387951 |
2015 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heterozygosity of the Hexim-1 gene in the prostate cancer mice model and the TRAMP-C2 cell line, leads to increased Cdk9-dependent serine phosphorylation on protein targets such as the androgen receptor (AR) and the TGF-β-dependent downstream transcription factors, such as the SMAD proteins.
|
22095517 |
2012 |
TNFRSF25
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Immunoblotting analysis and real-time quantitative-PCR showed increase in AGS3 expression in the metastatic cell lines LNCaP (~3-fold), MDA PCa 2b (~2-fold), DU 145 (~2-fold) and TRAMP-C1 (~20-fold) but not in PC3 (~1-fold), relative to control RWPE-1.
|
31215992 |
2019 |
TNFRSF25
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, interductal fibroblast-like cells expand in PB-MYC and ERG/PTEN tumors, whereas in TRAMP PCa they expand little and stromal cells invade into intraductal adenomas.
|
27935821 |
2017 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
In an alternate approach to characterize smoking-induced oncogenic alterations, we also explored the effects of nicotine in human prostate cancer cells and prostate cancer-prone TRAMP mice.
|
26719530 |
2016 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, daily intake of DI prevents PCa progression in TRAMP mice, suggesting the possible effectiveness of the immunostimulant herbal products on prevention of PCa progression after diagnosis of low-risk PCa.
|
29861778 |
2018 |
TNFRSF25
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In line with this, progressive decrease of ligand-dependent corepressor expression was observed in the PCa TRAMP mouse model with increasing age.
|
21856747 |
2011 |
TNFRSF25
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the TRAMP mouse model of prostate cancer, NQO1 was highly expressed in tumor cells.
|
25125658 |
2014 |
TNFRSF25
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, we have used B16-OVA melanoma, Panc-OVA pancreatic, and TRAMP-C1 prostate cancer mouse tumor models to test therapeutic efficacy of ISCOMATRIX vaccines combined with other immune modulators.
|
25646304 |
2015 |